Role of urokinase receptor in tumor progression and development
- PMID: 23843896
- PMCID: PMC3706692
- DOI: 10.7150/thno.4218
Role of urokinase receptor in tumor progression and development
Abstract
Elevated level of urokinase receptor (uPAR) is detected in various aggressive cancer types and is closely associated with poor prognosis of cancers. Binding of uPA to uPAR triggers the conversion of plasminogen to plasmin and the subsequent activation of metalloproteinases. These events confer tumor cells with the capability to degrade the components of the surrounding extracellular matrix, thus contributing to tumor cell invasion and metastasis. uPA-uPAR interaction also elicits signals that stimulate cell proliferation/survival and the expression of tumor-promoting genes, thus assisting tumor development. In addition to its interaction with uPA, uPAR also interacts with vitronectin and this interaction promotes cancer metastasis by activating Rac and stimulating cell migration. Although underlying mechanisms are yet to be fully elucidated, uPAR has been shown to facilitate epithelial-mesenchymal transition (EMT) and induce cancer stem cell-like properties in breast cancer cells. The fact that uPAR lacks intracellular domain suggests that its signaling must be mediated through its co-receptors. Indeed, uPAR interacts with diverse transmembrane proteins including integrins, ENDO180, G protein-coupled receptors and growth factor receptors in cancer cells and these interactions are proven to be critical for the role of uPAR in tumorigenesis. Inhibitory peptide that prevents uPA-uPAR interaction has shown the promise to prolong patients' survival in the early stage of clinical trial. The importance of uPAR's co-receptor in uPAR's tumor-promoting effects implicate that anti-cancer therapeutic agents may also be developed by disrupting the interactions between uPAR and its functional partners.
Keywords: uPA; uPAR; urokinase receptor.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures

Similar articles
-
TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.Exp Eye Res. 2013 Oct;115:13-21. doi: 10.1016/j.exer.2013.06.020. Epub 2013 Jun 28. Exp Eye Res. 2013. PMID: 23810810
-
Downregulation of uPAR promotes urokinase translocation into the nucleus and epithelial to mesenchymal transition in neuroblastoma.J Cell Physiol. 2020 Sep;235(9):6268-6286. doi: 10.1002/jcp.29555. Epub 2020 Jan 28. J Cell Physiol. 2020. PMID: 31990070 Free PMC article.
-
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.J Cell Sci. 2008 Nov 15;121(Pt 22):3747-56. doi: 10.1242/jcs.029769. Epub 2008 Oct 21. J Cell Sci. 2008. PMID: 18940913 Free PMC article.
-
The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.Curr Pharm Des. 2011;17(19):1944-61. doi: 10.2174/138161211796718143. Curr Pharm Des. 2011. PMID: 21711235 Review.
-
Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.Curr Protein Pept Sci. 2018;19(12):1155-1163. doi: 10.2174/1389203718666171030103801. Curr Protein Pept Sci. 2018. PMID: 29086689 Review.
Cited by
-
Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing.Mol Ther Nucleic Acids. 2016 Nov 15;5(11):e386. doi: 10.1038/mtna.2016.91. Mol Ther Nucleic Acids. 2016. PMID: 27845768 Free PMC article.
-
ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer.Cancers (Basel). 2023 May 12;15(10):2734. doi: 10.3390/cancers15102734. Cancers (Basel). 2023. PMID: 37345070 Free PMC article.
-
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.Cancers (Basel). 2024 Mar 5;16(5):1050. doi: 10.3390/cancers16051050. Cancers (Basel). 2024. PMID: 38473407 Free PMC article.
-
uPAR promotes tumor-like biologic behaviors of fibroblast-like synoviocytes through PI3K/Akt signaling pathway in patients with rheumatoid arthritis.Cell Mol Immunol. 2018 Feb;15(2):171-181. doi: 10.1038/cmi.2016.60. Epub 2017 Jan 16. Cell Mol Immunol. 2018. PMID: 28090093 Free PMC article.
-
Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR.Mol Oncol. 2015 Aug;9(7):1312-23. doi: 10.1016/j.molonc.2015.03.004. Epub 2015 Mar 24. Mol Oncol. 2015. PMID: 25841765 Free PMC article.
References
-
- Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–284. - PubMed
-
- Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004;10:39–49. - PubMed
-
- Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res. 2003:S46–58. - PubMed
-
- Tyndall JD, Kelso MJ, Clingan P, Ranson M. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. Recent Pat Anticancer Drug Discov. 2008;3:1–13. - PubMed
-
- Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Wurtz SO, Brunner N, Gold MA. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111:89–94. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous